Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.57 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 11/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386535 | 0.91 | RXRA (0.48) | RXRANR1H2NR1H3RIPK3RET | |
| SCHEMBL2389451 | 0.90 | RXRA (0.54) | RXRANR1H2NR1H3RIPK3RET | |
| SCHEMBL5610648 | 0.89 | RXRA (0.53) | RXRANR1H2NR1H3RIPK3RET | |
| SCHEMBL2388058 | 0.89 | RXRA (0.51) | RXRANR1H2NR1H3RIPK3RET | |
| SCHEMBL2388279 | 0.87 | RXRA (0.48) | RXRANR1H2NR1H3RIPK3RET | |
| SCHEMBL2389052 | 0.86 | RXRA (0.67) | RXRANR1H2NR1H3RET | |
| SCHEMBL2386459 | 0.85 | RXRA (0.65) | RXRANR1H2NR1H3RIPK3RET | |
| SCHEMBL2390920 | 0.85 | RXRA (0.67) | RXRANR1H2NR1H3RETKDM4E | |
| SCHEMBL2389274 | 0.84 | RXRA (0.65) | RXRANR1H2NR1H3RETKDM4E | |
| SCHEMBL2389801 | 0.84 | RXRA (0.65) | RXRANR1H2NR1H3RIPK3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482366-B2 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2009-01-27 | — | — | US | claimed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | claimed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | claimed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | claimed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7482366-B2 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | RXRA 20/4885NR1H2 1/4885NR1H3 3/4885 |
| US-20050080111-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | RXRA 16/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20100056582-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | RXRA 16/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.